Clinical Research
Filter News
Found 138,516 articles
-
September 24 is World Cancer Research Day, and September is Childhood Cancer Awareness Month. BioSpace spoke with leaders from three companies tackling pediatric glioma.
-
One-year data indicates Biogen’s tofersen for SOD1-ALS, slows the decline of the disease through the lowering of SOD1 protein and neurofilament levels.
-
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
-
Recently published research into repairing nerve damage caused by injury may also pay off in treating some of the most vexing neurodegenerative diseases like Alzheimer’s.
-
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
-
New FDA Draft Guidance Aims to Protect Children who Participate in Clinical Trials
9/23/2022
Today, the U.S. Food and Drug Administration issued a draft guidance that, when finalized, will provide the agency's perspective on the ethical considerations for including and protecting children in clinical trials.
-
Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle
9/23/2022
The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
-
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
9/23/2022
Alimera Sciences, Inc. announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network.
-
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
9/23/2022
Immutep Limited is pleased to announce it has received a €1,804,341 (~ A$2,693,046 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).
-
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting
9/23/2022
Humacyte, Inc. today announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma.
-
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
9/23/2022
ABVC Biopharma, Inc. today announced enrollment progress in the Phase II Part 2 clinical study of the Company’s ADHD medicine, ABV-1505, currently being conducted at five prestigious medical centers in Taiwan.
-
TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)
9/23/2022
Pulnovo Medical Limited, a globally recognized OTM platform, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on the world's largest and most influential American transcatheter cardiovascular therapy conference (TCT 2022).
-
ZIVO Bioscience CEO Issues Letter to Shareholders
9/23/2022
Zivo Bioscience, Inc. today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
-
AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia
9/23/2022
AEON Biopharma, Inc. today announced positive topline results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the neck.
-
Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial
9/23/2022
Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.
-
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET
9/23/2022
CASI Pharmaceuticals, Inc. today announced that CASI Biopharmaceuticals (Wuxi) Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. ("CASI Wuxi"), entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP ("Jiadao Gongcheng"), pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology (Tianjin) Co., Ltd.
-
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
9/23/2022
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx ® -Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma.
-
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
9/23/2022
Spectrum Pharmaceuticals, Inc. today announced that it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million.
-
Shares of Spectrum Pharmaceuticals plunged 33% upon the release of briefing documents for an FDA advisory meeting regarding poziotinib
-
Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.